TF and cancer: The ADC approach is similar to that of fVII-targeted photodynamic therapy that we developed earlier [49], in which fVII (with a coagulation active site mutation K341A) serves as a targeting molecule to selectively deliver photosensitizers into TF-expressing cancer cells [29,30,35,36], tumor VECs [15,29,30,35,36] and CSCs [15] via internalization (reaching peak internalization at 30 minutes post fVII binding to TF) [29].